Premium
Phase I study of L‐alanosine (NSC 15353)
Author(s) -
Goldsmith Michael A.,
Ohnuma Takao,
Spigelman Melvin,
Greenspan Ezra M.,
Holland James F.
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830201)51:3<378::aid-cncr2820510303>3.0.co;2-i
Subject(s) - mucositis , medicine , erythema , limiting , toxicity , oral cavity , gastroenterology , dermatology , pharmacology , dentistry , mechanical engineering , engineering
L‐alanosine (NSC I5353) is a newly developed antitumor antibiotic which acts as an inhibitor of purine intermediary metabolism. Experimental antitumor activity was demonstrated in a variety of murine neoplasms. A phase I trial was undertaken on a daily × 5 (d × 5) schedule in 22 evaluable patients. Dose limiting toxicity was an oral mucositis characterized by beefy red oral, lingual and pharyngeal erythema. The maximum tolerated dose is 320 mg/m 2 /d × 5 every three weeks. The recommended dose for phase II evaluation is 160 mg/m 2 /d × 5 every three weeks.